RxDoctor Payments Data

Lexi Jacobson, PA

Physician Assistant · Reno, NVNPI 1437711330

Payments from drug & device makers

$3,362in general payments, 2019–2025

Across 56 payments — averaging $60.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cipla USA Inc.$1K
  • Boston Scientific$457
  • Johnson & Johnson$438
  • Astellas Pharma US Inc$244
  • AbbVie$147
  • Teleflex LLC$145
  • plus $836 from 12 others

What the payments were for

  • Food & beverage$3,01890%
  • Education$34410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,362 in reported general payments places this provider in the 80th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$108,962
Medicare patients
800
Services billed
2,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron161$147,395
GemtesaVibegron83$87,338
Methenamine Hippurate143$16,751
PremarinEstrogens, Conjugated22$10,033
Tamsulosin Hcl403$7,919
Potassium Citrate ErPotassium Citrate36$6,079
Trospium Chloride ErTrospium Chloride19$5,933
Estradiol81$5,376
Solifenacin Succinate31$3,403
Finasteride199$3,329
Oxybutynin Chloride ErOxybutynin Chloride102$3,087
Fesoterodine Fumarate ErFesoterodine Fumarate13$2,628
Silodosin14$1,910
Testosterone Cypionate33$1,830
Tolterodine Tartrate ErTolterodine Tartrate16$1,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$244$147,395161 claims
Sumitomo Pharma America, Inc.Gemtesa$144$87,33883 claims
PfizerPremarin$29$10,03322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →